PrimePCR™Assay Validation Report

Gene Information Name TAF12 RNA polymerase II, TATA box binding (TBP)-associated factor, 20kDa

Gene Symbol TAF12

Organism Human

Gene Summary Control of transcription by RNA polymerase II involves the basal transcription machinery which is a collection of . These proteins with RNA polymerase II assemble into complexes which are modulated by transactivator proteins that bind to cis-regulatory elements located adjacent to the transcription start site. Some modulators interact directly with the basal complex whereas others may act as bridging proteins linking transactivators to the basal transcription factors. Some of these associated factors are weakly attached while others are tightly associated with TBP in the TFIID complex. Among the latter are the TAF proteins. Different TAFs are predicted to mediate the function of distinct transcriptional activators for a variety of gene promoters and RNA polymerases. TAF12 interacts directly with TBP as well as with TAF2I. Two transcript variants encoding the same protein have been found for this gene.

Gene Aliases TAF2J, TAFII20

RefSeq Accession No. NC_000001.10, NT_004610.19

UniGene ID Hs.530251

Ensembl Gene ID ENSG00000120656

Entrez Gene ID 6883

Assay Information Unique Assay ID qHsaCIP0032940

Assay Type Probe - Validation information is for the primer pair using SYBR® Green detection

Detected Coding Transcript(s) ENST00000373824, ENST00000263974

Amplicon Context Sequence AAAATCCAAGGATGAGATGGCTGAGTTCTCAGCTCAAGTATCTCCAAATACATTG CTGTCCATTCCCTGACCTTTCCGTGTGTTATTTCTTGGTTGTTTTCCGGATCAATG CCATTCTCTGTTTGTGAGCTTCTGTGGTGCAAGCTTTT

Amplicon Length (bp) 119

Chromosome Location 1:28929969-28931914

Assay Design Intron-spanning

Purification Desalted

Validation Results Efficiency (%) 97

Page 1/5 PrimePCR™Assay Validation Report

R2 0.9995

cDNA Cq 19.39

cDNA Tm (Celsius) 81.5

gDNA Cq 36.19

Specificity (%) 100 Information to assist with data interpretation is provided at the end of this report.

Page 2/5 PrimePCR™Assay Validation Report

TAF12, Human

Amplification Plot Amplification of cDNA generated from 25 ng of universal reference RNA

Melt Peak Melt curve analysis of above amplification

Standard Curve Standard curve generated using 20 million copies of template diluted 10-fold to 20 copies

Page 3/5 PrimePCR™Assay Validation Report

Products used to generate validation data Real-Time PCR Instrument CFX384 Real-Time PCR Detection System

Reverse Transcription Reagent iScript™ Advanced cDNA Synthesis Kit for RT-qPCR

Real-Time PCR Supermix SsoAdvanced™ SYBR® Green Supermix

Experimental Sample qPCR Human Reference Total RNA

Data Interpretation Unique Assay ID This is a unique identifier that can be used to identify the assay in the literature and online.

Detected Coding Transcript(s) This is a list of the Ensembl transcript ID(s) that this assay will detect. Details for each transcript can be found on the Ensembl website at www.ensembl.org.

Amplicon Context Sequence This is the amplicon sequence with additional base pairs added to the beginning and/or end of the sequence. This is in accordance with the minimum information for the publication of real-time quantitative PCR experiments (MIQE) guidelines. For details, please refer to the following publication, "Primer Sequence Disclosure: A Clarification of the MIQE Guidelines" (Bustin et al 2011).

Chromosome Location This is the chromosomal location of the amplicon context sequence within the genome.

Assay Design Exonic: Primers sit within the same exon in the mRNA transcript and can potentially co-amplify genomic DNA. If performing analysis, it is suggested that the samples be treated with a DNase to eliminate potential unwanted signal from contaminating genomic DNA.

Exon-exon junction: One primer sits on an exon-exon junction in mRNA. When performing gene expression analysis, this design approach will prevent unwanted signal from contaminating genomic DNA.

Intron-spanning: Primers sit within different exons while spanning a large intron in the mRNA (intron is greater than 750bp). When performing gene expression analysis, this design approach should limit potential unwanted signal from contaminating genomic DNA.

Small intron-spanning: Primers sit within different exons with a short intron in between (intron is smaller than 750bp). Small introns may not prevent unwanted signal from contaminating genomic DNA.

Efficiency Assay efficiency was determined using a seven-point standard curve from 20 copies to 20 million copies. While an efficiency of 100% represents a perfect doubling of template at every cycle and is ideal, typical ranges of good assay efficiency are between 90-110%. For difficult targets, assay efficiency outside of this range are accepted and reported accordingly.

R2 The R2 represents the linearity of the standard curve and how well the standard curve data points fit the linear regression line. Acceptable values are >0.98.

Page 4/5 PrimePCR™Assay Validation Report

cDNA Cq Cq value obtained from 25ng of cDNA transcribed from universal RNA when performing wet-lab validation of the assay.

Note: Not all will be expressed at a detectable level in the universal RNA sample.

cDNA Tm Melting temperature of the amplicon when running a melt curve analysis.

gDNA Cq Cq value obtained when running the assay with 2.5ng of genomic DNA. This is more than a moderate level of genomic DNA contamination. Intron-spanning and exon-exon junction assay designs can minimize or eliminate genomic DNA detection.

Note: Genomic DNA contamination is often present at variable levels. If concerned about genomic DNA contamination, the genomic DNA contamination control assay is recommended to run with your sample to determine if genomic DNA levels are sufficient to negatively impact results.

Specificity This value is the percent of specific amplicon reads as measured by next generation sequencing (NGS). While 100% specificity is desirable, small decreases in specificity (<1%) can be due to NGS read errors. More significant reductions are likely due to co-amplification of homologous regions.

Note: Since gene expression can be cell type and condition specific, the exact level and impact of co-amplification in a given sample is impossible to predict. If co-amplification is detected, it should be taken into consideration and reported when analyzing gene expression results.

Page 5/5